• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 4
  3. Author

Online ISSN: 2515-8260

Volume9, Issue4

Assessment of role of SGLT2 inhibitors in elderly obese uncomplicated DM patients

    Shaheen Saeed, Parvez SaeedAnsari

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 4, Pages 393-397

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background:SGLT2 inhibitor treatment has been shown to have additional benefits
such as weight loss, renoprotective and cardioprotective effects. The present study was
conducted to assess role of SGLT2 inhibitors in elderly obese uncomplicated DM
patients.
Materials & Methods:84type II DM patients of both genders were prescribed
empagliflozin or dapagliflozin. FBG, PPBG, HbA1c, liverenzymes and kidney function
tests, complete urinalysis,serum lipids, protein excretion in spot urine were
recordedbefore and after the initiation of SGLT2 inhibitor.
Results: Out of 84 patients, males were 50 and 34 were females. SGLT2 inhibitor used
wereEmpagliflozin in 40 and Dapagliflozin in 44. Comorbidities were hyperlipidemia in
57, hypertension in 62, CAD in 12 and heart failure in 7 patients. Complications were
diabetic nephropathy in 15, diabetic retinopathy in 10 and diabetic neuropathy in 22
patients. The difference was significant (P< 0.05). Laboratory findings before and after
treatment in FBG (mg/dl) was 198.2 and 154.3, PPBG (mg/dl) was 276.2 and 235.9,
HbA1c (%) was 9.5 and 7.1, hemoglobin (g/dl) was 13.5 and 14.2, hematocrit (%) was
43.2 and 45.0, urea (mg/dl) was 36.4 and 38.7, creatinine (mg/dl) was 0.8 and 0.9 and
eGFR (mL/min/1.73 m2) was 84.2 and 79.5 respectively. The difference was significant
(P< 0.05).
Conclusion: Glycemic control was successfully achieved with SGLT2 inhibitor
treatment in type II DM patients.
Keywords:
    Diabetes mellitus Empagliflozin SGLT2 inhibitor
  • PDF (146 K)
  • XML
(2022). Assessment of role of SGLT2 inhibitors in elderly obese uncomplicated DM patients. European Journal of Molecular & Clinical Medicine, 9(4), 393-397.
Shaheen Saeed, Parvez SaeedAnsari. "Assessment of role of SGLT2 inhibitors in elderly obese uncomplicated DM patients". European Journal of Molecular & Clinical Medicine, 9, 4, 2022, 393-397.
(2022). 'Assessment of role of SGLT2 inhibitors in elderly obese uncomplicated DM patients', European Journal of Molecular & Clinical Medicine, 9(4), pp. 393-397.
Assessment of role of SGLT2 inhibitors in elderly obese uncomplicated DM patients. European Journal of Molecular & Clinical Medicine, 2022; 9(4): 393-397.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 70
  • PDF Download: 95
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus